OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) is a micro-cap player in the medical cannabis space that has broken out to the upside following another constructive mid-trend bullish basing pattern. OWC stock has generally continued to outperform the space. We have been supportive on the name because of its strong strategic balance and exposure to beneficial governance standards in Israel. But in many ways, it remains somewhat of a black box. That may be changing now, as the company begins to open up to the world in terms of exposure. This starts with its announcement that it will be presenting at the Wall Street Conference. The event will be held at the Hilton Doubletree Hotel and Conference Center in Deerfield Beach/ Boca Raton, Florida, on Wednesday, March 1, 2017.
According to the company’s recent release, the Wall Street Conference is the premiere conference in the venture capital arena and small-cap marketplace. Conference participants include industry leaders from the hedge fund, investment banking, and private equity worlds, as well as sophisticated investors, who attend to discuss significant trends in the financial markets.
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) bills itself as a company that engages in the research and development of Cannabis-based medical products. The company provides medical products for the treatment of various medical conditions and/or diseases, such as multiple myeloma, psoriasis, PTSD, and migraines; and delivery systems. It also provides consulting services to companies and governmental agencies related to international medical cannabis protocols and regulations.
OWCP through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals, treatments and unique delivery systems for the effective delivery and dosage of medical cannabis.
All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
OWCP’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.
The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. The company was formerly known as Dynamic Applications Corp. OWC Pharmaceutical Research Corp. was founded in 2008 and is based in Petach Tikva, Israel.
According to company materials, “OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively “OWC” or the “Company”) conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators. The Company’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.”
Find out when OWC stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted in the recent press coverage, Ziv Turner, OWCP’s VP Business development and Managing Director of One World Cannabis, the Company’s wholly-owned subsidiary, will provide conference attendees with an update about the Company’s progress, specifically focused on its research and products in development, and most importantly the Company’s plans for the future, sales and marketing in the US, Canada and Europe this year (2017). The Company is currently scheduled to give its presentation on or around 3:30 PM, as a follow to its advisory board member, Mr. Jeffery Friedland’s key tone session. Other management team members, Mr. Mordehai Bignitz, Chairman and CEO and Dr. Yehuda Baruch, Chief Science Officer will also be available for one-on-one discussions during the conference.
Traders will note 45% added to share values of the listing over the past month of action. This is emblematic of the stock. OWC stock has a history of dramatic rallies. Furthermore, the listing has witnessed a pop in interest, as transaction volume levels have recently pushed about 10% over the long run average. Since we last covered the name, the stock has moved 39.3% higher.
At this time, carrying a capital value in the market of $129.4M, OWC Pharmaceutical has about $90K in cash on the books, which stands against about $186K in total current liabilities. The company is pre-revenue at this point. We will update the story again soon as developments transpire. For continuing coverage on shares of OWC stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!